Cargando…

Relugolix: A Review in Advanced Prostate Cancer

Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivot...

Descripción completa

Detalles Bibliográficos
Autor principal: Shirley, Matt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/
https://www.ncbi.nlm.nih.gov/pubmed/36652173
http://dx.doi.org/10.1007/s11523-022-00944-4
_version_ 1785044820107984896
author Shirley, Matt
author_facet Shirley, Matt
author_sort Shirley, Matt
collection PubMed
description Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of > 90%, a rate that was non-inferior to that provided by intramuscular leuprolide depot every 3 months (with an exploratory analysis further indicating the superiority of relugolix over leuprolide). Relugolix was generally well tolerated, having an adverse event profile that is consistent with testosterone suppression. Furthermore, there is evidence that relugolix may be associated with a lower risk of major adverse cardiac events compared with leuprolide. With the ability to provide the rapid testosterone suppression (with no initial surge in testosterone upon treatment initiation) combined with the benefits of oral administration and potentially improved cardiac safety, relugolix presents a valuable treatment option for men with advanced prostate cancer where androgen deprivation therapy is indicated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-022-00944-4.
format Online
Article
Text
id pubmed-10198864
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-101988642023-05-21 Relugolix: A Review in Advanced Prostate Cancer Shirley, Matt Target Oncol Adis Drug Evaluation Relugolix (Orgovyx(®)), an orally active nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist that provides rapid testosterone suppression, is indicated in the USA for the treatment of advanced prostate cancer and in the EU for advanced hormone-sensitive prostate cancer. In the pivotal phase III HERO trial in men with advanced prostate cancer, once-daily oral relugolix (with a loading dose on day 1) led to a sustained castration rate over 48 weeks of treatment of > 90%, a rate that was non-inferior to that provided by intramuscular leuprolide depot every 3 months (with an exploratory analysis further indicating the superiority of relugolix over leuprolide). Relugolix was generally well tolerated, having an adverse event profile that is consistent with testosterone suppression. Furthermore, there is evidence that relugolix may be associated with a lower risk of major adverse cardiac events compared with leuprolide. With the ability to provide the rapid testosterone suppression (with no initial surge in testosterone upon treatment initiation) combined with the benefits of oral administration and potentially improved cardiac safety, relugolix presents a valuable treatment option for men with advanced prostate cancer where androgen deprivation therapy is indicated. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11523-022-00944-4. Springer International Publishing 2023-01-18 2023 /pmc/articles/PMC10198864/ /pubmed/36652173 http://dx.doi.org/10.1007/s11523-022-00944-4 Text en © Springer Nature 2023, corrected publication 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Adis Drug Evaluation
Shirley, Matt
Relugolix: A Review in Advanced Prostate Cancer
title Relugolix: A Review in Advanced Prostate Cancer
title_full Relugolix: A Review in Advanced Prostate Cancer
title_fullStr Relugolix: A Review in Advanced Prostate Cancer
title_full_unstemmed Relugolix: A Review in Advanced Prostate Cancer
title_short Relugolix: A Review in Advanced Prostate Cancer
title_sort relugolix: a review in advanced prostate cancer
topic Adis Drug Evaluation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198864/
https://www.ncbi.nlm.nih.gov/pubmed/36652173
http://dx.doi.org/10.1007/s11523-022-00944-4
work_keys_str_mv AT shirleymatt relugolixareviewinadvancedprostatecancer